Targeting thrombopoietin to treat blood cancers
Official title: Thrombopoietin Targeting in Myeloproliferative Neoplasms
Funded at Aronora, INC. · NIH-10875331 · Data updated 2026-11-12
This study is testing a new drug called AB062 to help people with myeloproliferative neoplasms (MPNs) by lowering the levels of a protein that causes too many blood cells to be made, which could lead to better health and a better quality of life for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aronora, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project start | April 22, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $669,111 |
| NIH project number | 5R44HL162386-03 |
| Project ID | NIH-10875331 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with early-stage MPNs or those who do not have a confirmed diagnosis of myeloproliferative neoplasms may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for patients with myeloproliferative neoplasms (MPNs), a type of blood cancer characterized by the overproduction of blood cells. The approach involves using a novel drug candidate, AB062, which is an antisense oligonucleotide designed to inhibit the production of thrombopoietin, a protein that stimulates blood cell production. By reducing thrombopoietin levels, the treatment aims to decrease the number of abnormal blood cells while preserving healthy blood cell production. This could potentially improve patient outcomes and quality of life for those suffering from advanced MPNs.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that significantly improves survival and quality of life for patients with myeloproliferative neoplasms.
How similar studies have gone: While the approach of targeting thrombopoietin is innovative, similar strategies in the field of blood cancers have shown promise, indicating potential for success.
Where this research is happening
-
Aronora, INC.
Portland, United States Active
Researchers
- Principal investigator: Lorentz, Christina U — Aronora, INC.
- Study coordinator: Lorentz, Christina U
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.